EVER PHARMA

STROKE

TBI

DEMENTIA

Kim et al., 2019

Cerebrolysin – Significant Improvement of Consciousness Level After Stroke

Effective pharmacological treatment for MCS patients

Effects of Cerebrolysin in patients with minimally conscious state after stroke: an observational retrospective clinical study.
Kim et al., Front Neurol. 2019; 10: 803.

Cerebrolysin®

Reconnecting Neurons.
Empowering for Life.

Significant improvement of consciousness in post-stroke MCS

→ Risk reduction for long-term severe disability and institutionalization

→ Stronger improvement in oromotor functions and arousal with Cerebrolysin

→ Increased duration of patients arousal



Figure 1: Changes of JFK -CRS total scores in both groups from admission to discharge.
**p < 0.05 comparing CRS-R total scores at discharge with scores at admission in each group by paired t-test, and comparing Cerebrolysin group vs. control group over time by linear mixed model (LMM).*

Improvement of MCS twice as high in stroke patients treated with Cerebrolysin

- **Clinically relevant improvement of MCS through Cerebrolysin (CRS-R 4.2 vs. 2.3).**
- **Cerebrolysin is the only effective compound in improving the CRS-R scores irrespective of age, sex, laterality of lesions, location of lesions, and the etiology of the stroke.**

Title	Effects of Cerebrolysin® in Patients with Minimally Conscious State after Stroke: An Observational Retrospective Clinical Study
Patients	**N=75 patients (43 Cerebrolysin + 32 Placebo)** **Ischemic and/ or hemorrhagic stroke patients with MCS** Cerebrolysin group = Cerebrolysin + standard rehabilitation treatment Placebo group = Saline + standard rehabilitation treatment
Treatment	10ml/day IV for 20 days Primary endpoint = the result of the Coma Recovery Scale-Revised (CRS-R) at admission and discharge.

ABBREVIATED PRESCRIBING INFORMATION. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.

Copyright © 2020 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria

CERE/INT/03/2020/10